Table 1.

Patient characteristics of included study populations.

Study	N	No of prostate cancer deaths	Total person- years	Person-years at risk median (min- max)	Number of SNPs with imputation quality>=0.75
			PRACTICAL
CAPS	412	49	3 476,6	9.3 (0.4–11.8)	5,752,274Ɨ
CAPS1	492	214	3 120,2	7.1 (0.1–11.8)	8,933,855$
CAPS2	1493	331	11 644,6	9.1 (0–11.8)	8,715,366$
CPCS	925	97	1 772,1	1.3 (0.1–18.1)	5,550,954Ɨ
EPIC	404	35	467,4	0 (0–13.2)	5,503,395Ɨ
ESTHER	300	22	2 179,9	7.7 (0.1–9.8)	5,495,692Ɨ
FHCRC	760	46	7 716,6	8.1 (0.2–18.1)	5,532,283Ɨ
MAYO	737	40	4 612,8	6.8 (0.1–13.9)	5,555,791Ɨ
MCCS_PCFS	1663	139	41 656,4	22.6 (0–71.2)	5,425,082Ɨ
MEC	581	15	3 531,5	5.8 (0.1–13.1)	5,462,203Ɨ
PCMUS	57	7	68,9	1.1 (0.1–4.0)	5,359,978Ɨ
SEARCH	1369	70	4 966,3	3.7 (0.1–4.5)	5,510,831Ɨ
STHM1	2199	71	8 247,2	3.9 (0–4.3)	5,724,947Ɨ
TAMPERE	2463	248	21 037,6	7.8 (0.8–20.9)	6,455,082Ɨ
UKGPCS	4344	826	22 906,2	4.3 (0–27.3)	5,485,041Ɨ
UKGPCS1	1783	457	13 689,0	7.0 (0.1–30.0)	9,536,409Ɣ
UKGPCS2	772	189	6 961,8	9.1 (0–24.9)	1,235,003Ϯ
ULM	365	32	3 151,9	9.0 (0.6–22.0)	5,457,321Ɨ
UTAH	122	27	603,7	4.0 (0.1–26.9)	5,641,408Ɨ
			BPC3
ATBC	245	133	1 426,2	5.8 (0–19.9)	8,232,459§
CPSII	636	79	5 859,4	9.2 (0.3–16.3)	7,448,367§
EPIC	431	159	2 197,3	5.2 (0–14.3)	7,612,553§
HPFS	214	37	1 616,6	7.6 (0.1–14.4)	7,539,277§
MEC	244	23	1 868,3	7.7 (0.9–15.4)	7,571,269§
PHS	298	97	2 811,8	9.4 (0–24.7)	7,569,352§
PLCO	714	70	4 664,5	6.7 (0.1–12.9)	7,526,690§
Total	24023	3513	182 254,8
CONOR	1496	791	8741.4	5.0 (0.08–20.8)

^ƗGenotyped on a custum Illumina SNP infimum chip (iCOGS) with 211,155 SNPs, enriched in regions associated with incidence of prostate, breast and ovarian cancer.

^ƔGenotyped on Illumina Infinium HumanHap 550 Array.

^ϮGenotyped on Illumina iSELECT in 43,671 SNPs.

^$Genotyped on Affymetrix GeneChip 5.0K or 500K.

^§Genotyped on Illumina Human 610 or 610K.